This is in the form of urate-lowering
therapy,where the aim is (i) to reduce uric
acid levels to below that necessary for
crystalformation, and (ii) to dissolve existing
crystals, thereby reducing the frequency
and severity of recurrent episodes and the
development of joint damage and tophi.